Weeks after Keytruda CRL in high-risk TNBC, Merck claims a win after data mature. How soon will it return to FDA?
There’s been much afoot regarding Merck’s attempts to expand its blockbuster Keytruda drug into high-risk, early-stage triple-negative breast cancer so far in 2021.
In early …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
